Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote In favor of Your Favored Kind Of Attire - 25 Destinations Where Airfare Is Dropping The Most For Spring 2026, Per Dollar Flight Club Analysis
- 3Figure out How to Amplify Innovation and Infotainment Frameworks for Senior Drivers in SUVs
- 4Young Muslims in Germany feel left out of Mideast debate, experts say
- 5Vote In favor of Your Favored Web-based Venture Stage
- Traveling Alone: An Excursion of Self-Disclosure
- The 10 Most Famous Works of art Ever
- UN rights chief: Israel's new Gaza aid agency rules 'outrageous'
- France to build new nuclear aircraft carrier, Macron says
- Pick Your #1 Japanese Food
- What do teens and tweens want for the holidays? E-bikes, gift cards and lip tints.
- Support Your Investment funds with These Individual accounting Thoughts
- Step by step instructions to Choose the Right Internet based Degree Program for Your Future
- The most effective method to Decisively Plan Your Nursing Profession for the Best Compensation Results
